环丙沙星与阿奇霉素鼻窦支架治疗慢性鼻窦炎的安全性与药代动力学
研究改良含环丙沙星(内层)和阿奇霉素(外层)的双层涂层鼻窦支架(CASS),体外评估药物释放,并在兔上评估安全性与药代动力学。结果显示涂层均匀,环丙沙星体外14天持续释放,体内12天释放78.92±7.67%环丙沙星和84.12±0.45%阿奇霉素,未见显著安全性异常。作者认为CASS可有效递送治疗水平抗生素,需进一步在临床前鼻窦炎模型验证疗效。
要点
- CASS含2 mg环丙沙星和5 mg阿奇霉素,涂层均匀,厚度分别为14.7±2.4 μm和28.1±4.6 μm。
- 体外环丙沙星14天持续释放,第7天释放86.2±3.4%,第14天99.2±5.1%。
- 兔体内12天释放78.92±7.67%环丙沙星和84.12±0.45%阿奇霉素,安全性指标无显著差异。
核心结论
- CASS可有效递送治疗水平的抗生素,需进一步在临床前鼻窦炎模型验证疗效。
研究设计与样本
- 研究用浸涂法制备含2 mg环丙沙星和5 mg阿奇霉素的CASS,体外评估涂层均匀性、药物释放和乳酸脱氢酶(LDH)试验14天,并在兔上经上颌窦置入评估安全性、耐受性和药代动力学。
主要发现
- 扫描电镜证实环丙沙星和阿奇霉素双层涂层均匀,厚度分别为14.7±2.4 μm和28.1±4.6 μm。
- 内层环丙沙星在盐溶液中14天持续释放,第7天释放86.2±3.4%,第14天释放99.2±5.1%。
- 兔体内置入12天后,环丙沙星释放78.92±7.67%,阿奇霉素释放84.12±0.45%。
- 置入CASS前后体重、白细胞计数和影像学变化无显著差异,与对侧对照相比未见显著组织学改变。
局限性
- 需进一步研究在临床前鼻窦炎模型中验证疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Previously, we developed a novel double-coated sinus stent containing ciprofloxacin (inner layer) and azithromycin (outer layer) (CASS), but released drug concentrations were found to be insufficient for clinical usage. Our objectives are to improve drug release of CASS and assess safety and pharmacokinetics in rabbits. METHODS: Dip coating was used to create the CASS with 2 mg ciprofloxacin and 5 mg azithromycin. A uniformed double coating was assessed with scanning electron microscopy (SEM), and the release patterns of both drugs and lactate dehydrogenase (LDH) assay were evaluated over 14 days in vitro. Safety, tolerability, and pharmacokinetics of the CASS were tested in rabbits through insertion into the maxillary sinus and evaluated with nasal endoscopy, CT scans, histology, blood counts and chemistries, and in vivo drug release. RESULTS: SEM confirmed the uniformity of the dual coating of ciprofloxacin and azithromycin, and thickness (μm) was found to be 14.7 ± 2.4 and 28.1 ± 4.6, respectively. The inner coated ciprofloxacin showed a sustained release over 14 days (release %) when soaked in saline solution (day 7, 86.2 ± 3.4 vs. day 14,99.2 ± 5.1). In vivo analysis showed that after 12 days, 78.92 ± 7.67% of CP and 84.12 ± 0.45% of AZ were released into the sinus. There were no significant differences in body weight, white blood cell counts, and radiographic changes before and after CASS placement. No significant histological changes were observed compared to the contralateral control side. CONCLUSION: Findings suggest that the CASS is an effective method for delivering therapeutic levels of antibiotics. Further studies are needed to validate efficacy in a preclinical sinusitis model. LEVEL OF EVIDENCE: N/A Laryngoscope, 134:3953-3959, 2024.
引用
- Lim DJ, Bicknell BT, Rivers N, et al. Safety and Pharmacokinetics of a Ciprofloxacin and Azithromycin Stent for Chronic Rhinosinusitis. Laryngoscope. 2024. PMID: 38563347. doi:10.1002/lary.31431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。